Piper Sandler Maintains Overweight on Kymera Therapeutics, Lowers Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Kymera Therapeutics (NASDAQ:KYMR), but lowered the price target from $58 to $38.
November 03, 2023 | 9:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on Kymera Therapeutics, but lowered the price target from $58 to $38.
The lowering of the price target by Piper Sandler could potentially lead to a decrease in the stock price of Kymera Therapeutics in the short term. However, the maintained Overweight rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100